Research programme: antibody therapeutics - MorphoSys/Novartis
Alternative Names: Anti-sclerostin antibody - Novartis/MorphoSys; Osteoporosis monoclonal antibody - Novartis/MorphSysLatest Information Update: 01 Aug 2024
At a glance
- Originator MorphoSys; Novartis
- Class Monoclonal antibodies
- Mechanism of Action SOST protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Inflammation; Osteoporosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Unknown (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in Unknown (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Osteoporosis in Unknown (Parenteral)